·CO-CEO of Asymchem Group
·MBA, Peking Univ.
·Over the past 20 years, Ms. Yang has coordinated the activities of more than ten subsidiaries of the Group and has made significant contributions guiding the company to become a leading global pharmaceutical outsourcing service enterprise
·MBA from Peking Univ.
·Member of Drug Toxicology Division, CNPHARS
·Visiting Professor of Pharmacy College, NKU
·Member of the Technological Strategy Alliance for the Development of New Anti-cancer Drugs in Binhai New Area, Tianjin
·Master of Finance, THU
·Served in CSRC Research Center and GEM Issuance Department for years
·10+ years in the stock market, participated in many major capital market system reforms of China Securities Requlatory Comission( CSRC )
·Extensive experience in corporate listing, investment and financial management
·MS, Peking Univ.
·18 years of industry experience in Novartis, served as clinical sciences therapeutic area head of ID and CV&M, and member of Disease Area Decision Board, Scientific Review Committee
·Focus on early development and strategy
? Executive Editor of China National Cancer Center Journal – JNCC
? Former Senior Medical Officer of the National Cancer Institute, USA
? Former Supervisory Medical Officer, National Center for Advancing Translational Sciences, National Institutes of Health, USA
? PhD in Cellular and Molecular Pathology, University of Birmingham; MPH (Master of Public Health) at Johns Hopkins University
?The US accreditation of the American Physician Qualification (ECFMG)
·MS, Peking Univ.
·EMBA, CEIBS
·18 years of experience in clinical trial data management and biostatistics
·10 years of experience in clinical trial at Pfizer, Novo Nordisk, NNIT, etc.
·5 years as a lecturer at Beijing Univ. Health Science Center
·20+ years of compliance experience in pharmaceutical industry
·Participated in the compilation of guidelines for NMPA, the Ministry of Industry and Information Technology etc.
·Rich experience in organization and implementation of EDC, CTMS, PV systems.
